A Single Ascending Dose (SAD) Study to Evaluate the Safety and Pharmacokinetics (PK) of ZB004 in Healthy Volunteers
Latest Information Update: 27 Feb 2025
At a glance
- Drugs ZB 004 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Sponsors Zenas BioPharma
- 15 Aug 2024 Status changed from active, no longer recruiting to completed.
- 22 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 20 Jun 2023 Planned End Date changed from 1 Dec 2023 to 1 Apr 2024.